[go: up one dir, main page]

DK1599450T3 - Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister - Google Patents

Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister

Info

Publication number
DK1599450T3
DK1599450T3 DK04715306T DK04715306T DK1599450T3 DK 1599450 T3 DK1599450 T3 DK 1599450T3 DK 04715306 T DK04715306 T DK 04715306T DK 04715306 T DK04715306 T DK 04715306T DK 1599450 T3 DK1599450 T3 DK 1599450T3
Authority
DK
Denmark
Prior art keywords
indan
quinolin
ylamino
hydroxyethyl
diethyl
Prior art date
Application number
DK04715306T
Other languages
English (en)
Inventor
Caspar Vogel
Olivier Lohse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1599450(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1599450T3 publication Critical patent/DK1599450T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK04715306T 2003-02-28 2004-02-27 Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister DK1599450T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45094503P 2003-02-28 2003-02-28
PCT/EP2004/001981 WO2004076422A1 (en) 2003-02-28 2004-02-27 Process for preparing 5-‘(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an adrenoceptor agonist

Publications (1)

Publication Number Publication Date
DK1599450T3 true DK1599450T3 (da) 2009-10-05

Family

ID=32927689

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04715306T DK1599450T3 (da) 2003-02-28 2004-02-27 Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister

Country Status (29)

Country Link
US (1) US7534890B2 (da)
EP (1) EP1599450B1 (da)
JP (1) JP4802089B2 (da)
KR (1) KR101076929B1 (da)
CN (1) CN100363349C (da)
AR (1) AR043406A1 (da)
AT (1) ATE434609T1 (da)
AU (1) AU2004215647B2 (da)
BR (1) BRPI0407904B1 (da)
CA (1) CA2517033C (da)
CL (1) CL2004000381A1 (da)
CY (1) CY1109442T1 (da)
DE (1) DE602004021675D1 (da)
DK (1) DK1599450T3 (da)
EC (1) ECSP055977A (da)
ES (1) ES2326974T3 (da)
IL (1) IL170138A (da)
MX (1) MXPA05009156A (da)
MY (1) MY142491A (da)
NO (1) NO331985B1 (da)
NZ (1) NZ541727A (da)
PE (1) PE20040956A1 (da)
PL (1) PL213932B1 (da)
PT (1) PT1599450E (da)
RU (1) RU2332405C2 (da)
SI (1) SI1599450T1 (da)
TW (1) TWI324150B (da)
WO (1) WO2004076422A1 (da)
ZA (1) ZA200506060B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
CA2521271C (en) * 2003-04-04 2011-01-04 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
MX2008016542A (es) 2006-06-30 2009-01-19 Novartis Ag Derivados de quinolina y sus composiciones farmaceuticas.
CA2679059A1 (en) 2007-02-28 2008-09-04 Cipla Limited Process for preparing isomers of carmoterol
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
CN104379566B (zh) * 2012-07-11 2016-08-24 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP2897937B1 (en) 2012-09-21 2017-12-06 Crystal Pharma S.A.U Process for the preparation of indacaterol and intermediates thereof
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
WO2014154841A1 (en) * 2013-03-27 2014-10-02 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
WO2015104718A2 (en) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
US10227305B2 (en) 2014-08-22 2019-03-12 G. Pratap REDDY Process for preparing indacaterol and salts thereof
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107074833B (zh) * 2015-07-21 2021-05-25 四川海思科制药有限公司 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109516974B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂的制备方法
WO2019135101A1 (en) 2018-01-02 2019-07-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN109988111A (zh) * 2019-05-06 2019-07-09 淮北师范大学 一种马来酸茚达特罗的杂质及其合成方法
CN110128339B (zh) * 2019-05-31 2022-03-08 苏州芝宇生物科技有限公司 一种茚达特罗及其盐衍生物的合成方法和合成用中间体
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
KR20000065219A (ko) * 1996-05-20 2000-11-06 마르크 젠너 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ES2326974T3 (es) 2009-10-22
RU2332405C2 (ru) 2008-08-27
CA2517033C (en) 2011-11-15
NZ541727A (en) 2008-07-31
RU2005129547A (ru) 2007-04-10
JP2006519206A (ja) 2006-08-24
MY142491A (en) 2010-11-30
PT1599450E (pt) 2009-08-31
BRPI0407904A (pt) 2006-02-14
KR101076929B1 (ko) 2011-10-26
BRPI0407904B1 (pt) 2016-09-20
CN100363349C (zh) 2008-01-23
MXPA05009156A (es) 2005-10-20
AU2004215647B2 (en) 2006-12-21
EP1599450B1 (en) 2009-06-24
ATE434609T1 (de) 2009-07-15
EP1599450A1 (en) 2005-11-30
WO2004076422A1 (en) 2004-09-10
AR043406A1 (es) 2005-07-27
TWI324150B (en) 2010-05-01
DE602004021675D1 (de) 2009-08-06
JP4802089B2 (ja) 2011-10-26
CL2004000381A1 (es) 2005-01-14
TW200505864A (en) 2005-02-16
CA2517033A1 (en) 2004-09-10
AU2004215647A1 (en) 2004-09-10
ECSP055977A (es) 2006-01-16
PL378358A1 (pl) 2006-03-20
PE20040956A1 (es) 2005-01-20
PL213932B1 (pl) 2013-05-31
NO20054452L (no) 2005-11-28
CY1109442T1 (el) 2014-08-13
NO20054452D0 (no) 2005-09-26
IL170138A (en) 2011-09-27
SI1599450T1 (sl) 2009-12-31
NO331985B1 (no) 2012-05-21
CN1753874A (zh) 2006-03-29
US7534890B2 (en) 2009-05-19
KR20050105258A (ko) 2005-11-03
US20060252794A1 (en) 2006-11-09
ZA200506060B (en) 2006-07-26
HK1086255A1 (en) 2006-09-15

Similar Documents

Publication Publication Date Title
DK1599450T3 (da) Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister
PH12020551304A1 (en) Novel crystalline forms
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE AS MPGES-1 INHIBITORS
WO2009025983A3 (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
SG11202102057SA (en) Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate
CL2014000270A1 (es) Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010).
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
CL2008000069A1 (es) Metodo de preparacion de compuestos derivados de 3,4-dihidroquinolina.
DK1163207T3 (da) Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin
NO20033288D0 (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
WO2009050352A3 (fr) Derives d'imidazolones, procede de preparation et applications biologiques
LT3921030T (lt) 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)karbamido dariniai, kaip kcnq stiprikliai
EP3860571A4 (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
ITMI20030799A1 (it) Dispositivo per la giunzione di due parti tra loro disposte a 90°.
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
DK1480953T3 (da) Fremgangsmåde til fremstilling af aripiprazol
DK1954690T3 (da) Benzamidforbindelser, der er anvendelige som inhibitorer af histondeacetylase
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
HUE072069T2 (hu) 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
DK1539746T3 (da) N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
ITMI20050247A1 (it) Processo per la preparazione di montelukast
WO2009030450A8 (en) Novel herbicides
WO2009122432A3 (en) Preparation of naphthoquinone compounds using 2, 3-dihalonapthoquinone
WO2006079720A8 (fr) Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants
ITMI20021533A1 (it) Processo per la preparazione di 2-acetossimetil-4-alo-but-1-il acetati